EXCELLENT (EXpanded CELL ENdocardiac Transplantation)

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

September 25, 2015

Primary Completion Date

March 15, 2024

Study Completion Date

March 15, 2024

Conditions
Acute Myocardial Infarction
Interventions
DRUG

PROTHERACYTES

ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters

DRUG

Standard Treatment for CHF post AMI

Trial Locations (13)

21079

CHU DIJON Hôpital François Mitterrand 14 rue Gaffarel, Dijon

25030

CHU BESANCON Hopital Jean Minjoz 3 Boulevard A.Fleming, Besançon

68100

GHRMSA, Mulhouse

Unknown

CHU de Grenoble, Grenoble

Institut Jacques Cartier, Massy

CHU Montpellier Arnaud-De-Villeneuve, Montpellier

Hôpital Haut Levèque, Pessac

Hôpital de Rangueil, Toulouse

University of Edinburgh, Edinburgh

Leeds University & Leeds Teaching Hospitals NHS Trust, Leeds

B15 2GW

Ninewells Hospital & Medical School, Dundee

BIRMINGHAM, Queen Elizabeth Hospital ,Mindelsohn Way,, Edgbaston

EC1A 7BE

Saint Bartholomew's Hospital W Smithfield,, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CellProthera

INDUSTRY